NCT05948943: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
- State
- Under way
- Phase
- Phase 2 and Phase 3
- People
- 232 planned
- Started
- 24 Nov 2023
- Primary completion
- 31 May 2028
- Arms
- Adult participants, alpelisib dose 1 (Stage 1), Adult participants, alpelisib dose 2 (Stage 1), Pediatric participants (6-17 years of age), alpelisib dose 2 (Stage 1), Pediatric participants (6-17 years of age), alpelisib dose 3 (Stage 1), Adult participants, alpelisib (Stage 2), Pediatric participants (6-17 years of age), alpelisib (Stage 2), Pediatric participants (0-5 years of age), alpelisib (Stage 2)
- Results
- None posted
- 17 Jul 2023: Trial registered
- 24 Nov 2023: Trial started